Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alpine Immune Sciences, Inc.

< Previous 1 2 Next >
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN VRTX
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.